ALLIANZ-SE
May 15, 2024
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514050487/en/
Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE)
1Q 2024:
- Total business volume advances 5.3 percent to 48.4 billion euros
- Operating profit increases 6.8 percent to 4.0 billion euros driven by the Property-Casualty business segment, supported by good results in the Asset Management and the Life/Health business segments
- Shareholders’ core net income rises to 2.5 billion euros, up by 15.7 percent
- Strong Solvency II capitalization ratio of 203 percent1
Outlook:
- 2024 operating profit target maintained at 14.8 billion euros, plus or minus 1 billion euros2
Other:
- 1 billion euros share buy-back started, 0.5 billion euros completed
1 |
Excluding the application of transitional measures for technical provisions and with quarterly dividend accrual. |
|
2 |
As always, natural catastrophes and adverse developments in the capital markets, as well as factors stated in our cautionary note regarding forward-looking statements may severely affect the operating profit and/or net income of our operations and the results of the Allianz Group. |
“Allianz’s strong results demonstrate the quality of our fundamentals, the value of consistency in the execution of our strategy, and the advantage of the broad talents and skillsets that are represented across our organization.
Our 5 percent business volume growth and double-digit increase in shareholders’ net income signal a strong start to the year. In our Property-Casualty business, solid top-line growth and bottom-line increase reflect the balance of growth and underwriting discipline. The Life/Health new business development confirmed the attractiveness of our broad product portfolio. In our Asset Management operations, net flows in the first quarter already exceeded last year’s full-year levels, underscoring the quality of our business and its value to clients.
Our proven track record of profitability, resilience, and consistent capital management make us the trusted partner of choice, especially in times of heightened uncertainty and accelerated change.”
- Oliver Bäte, Chief Executive Officer of Allianz SE
FINANCIAL HIGHLIGHTS |
Total business volume
1Q 2024: Total business volume rose by 5.3 percent to 48.4 billion euros, driven by all business segments. The Property-Casualty business segment recorded good price-driven growth, while the increase in the Life/Health business segment was primarily due to favorable sales momentum in the United States and Italy. Growth in the Asset Management business segment benefited from higher Assets under Management (AuM) and higher performance fees.
Internal growth was 7.5 percent, with contribution from all business segments.
Earnings
1Q 2024: Operating profit was strong at 4.0 (1Q 2023: 3.7) billion euros, up by 6.8 percent, driven by the Property-Casualty business segment and was broadly equally split between an increased operating insurance service result and a higher operating investment result. The operating profit was also supported by the Asset Management business segment due to higher net fee and commission income, while the Life/Health business segment achieved a good operating profit on last year’s level.
Shareholders’ core net income increased to 2.5 (2.2) billion euros due to a higher operating profit and non-operating result.
Net income attributable to shareholders rose to 2.5 (2.0) billion euros.
Core earnings per share (EPS)3 were 6.42 (5.43) euros.
The annualized core return on equity (RoE)3 was 17.4 percent (full year 2023: 16.1 percent).
3 |
Core EPS and core RoE calculation based on shareholders‘ core net income. |
Solvency II capitalization ratio
The Solvency II capitalization ratio was 203 percent at the end of 1Q 2024 compared with 206 percent at the end of 2023.
SEGMENTAL HIGHLIGHTS |
“Allianz’s strong performance in the first quarter demonstrates our unwavering commitment to value creation:
- In our Property-Casualty operations strong price-driven internal growth and strict underwriting discipline contributed to a very good increase in our operating profit. Benign natural catastrophes and higher investment income also supported the result.
- The widespread new business growth across our Life/Health segment underlined the quality of our global franchise in a competitive environment. Together with an attractive new business margin, this puts us in a very good position for continued value creation.
- In our Asset Management operations, strong third-party net inflows and exceptional performance fees demonstrated that we successfully managed a volatile capital markets environment. An increase in our third-party AuM and our competitive cost-income ratio position us well for profitable growth.
We had a very good start into the year and our ability to create value for our shareholders is supported by a strong Solvency II ratio of 203 percent. We confirm our full-year outlook of an operating profit of 14.8 billion euros, plus or minus 1 billion euros.”
- Claire-Marie Coste-Lepoutre, Chief Financial Officer of Allianz SE
Property-Casualty insurance: Very good operating profit
1Q 2024: Total business volume increased by 5.7 percent to 25.5 (24.1) billion euros. Adjusted for foreign currency translation and consolidation effects, internal growth was 7.5 percent. The main driver was very good growth of 9 percent in Retail, SME & Fleet. Commercial lines advanced by 4 percent.
Operating profit rose strongly by 10.4 percent to 2.1 (1.9) billion euros. Growth was equally split between an increased operating insurance service result and a higher operating investment result.
The combined ratio remained at an excellent level of 91.9 percent (91.9 percent). The loss ratio was 67.3 percent (67.0 percent) as lower run-off was partly offset by benign claims from natural catastrophes and a better attritional loss ratio. The expense ratio improved by 0.3 percentage points to 24.6 percent.
Life/Health insurance: Strong new business growth
1Q 2024: PVNBP, the present value of new business premiums, increased to 22.3 (18.5) billion euros, driven by higher volume in most entities. Allianz Re as well as positive sales momentum in Italy and the United States were the main contributors.
Operating profit remained strong at 1.3 (1.3) billion euros.
Contractual Service Margin (CSM) rose from 52.6 billion euros at the end of 2023, to 53.2 billion euros as of March 31, 2024, with strong normalized CSM growth of 1.7 percent. Performance was good across our entities while Allianz Re also benefited from a large contract.
The new business margin (NBM) increased to 5.7 percent (5.5 percent). The value of new business (VNB) surged to 1.3 (1.0) billion euros due to volume growth throughout most entities as well as an improved business mix.
Asset Management: Strong net inflows
1Q 2024: Operating revenues reached 2.0 billion euros, up 4.7 percent, driven by increased AuM and higher performance fees. Adjusted for foreign currency translation effects, operating revenues grew by 5.7 percent.
Operating profit increased to 773 (723) million euros, up by 7.0 percent. Adjusted for foreign currency translation effects, operating profit rose by 8.1 percent. The cost-income ratio (CIR) improved to 61.1 percent (62.0 percent).
Third-party assets under management amounted to 1.784 trillion euros as of March 31, 2024, up by 71 billion euros from the end of 2023. The main contributor was strong net inflows of 34.2 billion euros, with further positive contributions from currency translation and market effects.
Total assets under management were 2.297 trillion euros at the end of the first quarter 2024, up 73 billion euros from the end of 2023, in line with the results for the third-party assets under management.
1Q 2024 RESULTS TABLE |
Allianz Group - key figures 1st quarter 2024 |
|
|
|
|
|
|||||||
|
|
|
|
1Q 2024 |
|
1Q 2023 |
|
Delta |
|
|||
Total business volume |
€ bn |
48.4 |
|
46.0 |
|
5.3% |
|
|||||
- Property-Casualty |
|
|
€ bn |
25.5 |
|
24.1 |
|
5.7% |
|
|||
- Life/Health |
|
|
€ bn |
21.1 |
|
20.1 |
|
4.9% |
|
|||
- Asset Management |
|
€ bn |
2.0 |
|
1.9 |
|
4.7% |
|
||||
- Consolidation |
|
€ bn |
-0.2 |
|
-0.2 |
|
10.0% |
|
||||
Operating profit / loss |
|
€ mn |
3,986 |
|
3,731 |
|
6.8% |
|
||||
- Property-Casualty |
|
|
€ mn |
2,066 |
|
1,872 |
|
10.4% |
|
|||
- Life/Health |
|
|
€ mn |
1,327 |
|
1,320 |
|
0.5% |
|
|||
- Asset Management |
|
|
€ mn |
773 |
|
723 |
|
7.0% |
|
|||
- Corporate and Other |
|
|
€ mn |
-179 |
|
-176 |
|
1.6% |
|
|||
- Consolidation |
€ mn |
-2 |
|
-7 |
|
-72.8% |
|
|||||
Net income |
|
|
€ mn |
2,631 |
|
2,160 |
|
21.8% |
|
|||
- attributable to non-controlling interests |
€ mn |
156 |
|
128 |
|
21.7% |
|
|||||
- attributable to shareholders |
|
€ mn |
2,475 |
|
2,032 |
|
21.8% |
|
||||
Shareholders’ core net income1 |
€ mn |
2,513 |
|
2,173 |
|
15.7% |
|
|||||
Core earnings per share2 |
€ |
6.42 |
|
5.43 |
|
18.2% |
|
|||||
Additional KPIs |
|
|
|
|
|
|
|
|
||||
- Group |
|
Core return on equity3 |
% |
17.4% |
|
16.1% |
|
1.3% |
-p |
|||
- Property-Casualty |
|
Combined ratio |
% |
91.9% |
|
91.9% |
|
0.0% |
-p |
|||
- Life/Health |
|
New business margin |
% |
5.7% |
|
5.5% |
|
0.2% |
-p |
|||
- Asset Management |
|
Cost-income ratio |
% |
61.1% |
|
62.0% |
|
-0.8% |
-p |
|||
|
|
|
|
03/31/2024 |
|
12/31/2023 |
|
Delta |
|
|||
Shareholders' equity4 |
|
|
€ bn |
60.0 |
|
58.2 |
|
3.0% |
|
|||
Contractual service margin (net) |
€ bn |
33.2 |
|
32.7 |
|
1.4% |
|
|||||
Solvency II capitalization ratio5 |
% |
203% |
206% |
-3% |
-p |
|||||||
Third-party assets under management |
|
€ bn |
1,784 |
|
1,712 |
|
4.2% |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Please note: The figures are presented in millions of Euros, unless otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. |
||||||||||||
1_ |
Presents the portion of shareholders’ net income before non-operating market movements and before amortization of intangible assets from business combinations (including any related income tax effects). |
|||||||||||
2_ |
Calculated by dividing the respective period’s shareholders' core net income, adjusted for net financial charges related to undated subordinated bonds classified as shareholders' equity, by the weighted average number of shares outstanding (basic core EPS). |
|||||||||||
3_ |
Represents the annualized ratio of shareholders’ core net income to the average shareholders’ equity at the beginning and at the end of the period. Shareholders’ core net income is adjusted for net financial charges related to undated subordinated bonds classified as shareholders’ equity. From the average shareholders’ equity, undated subordinated bonds classified as shareholders’ equity, unrealized gains and losses from insurance contracts and other unrealized gains and losses are excluded. Annualized figures are not a forecast for full year numbers. For 1Q 2023, the core return on equity for the respective full year is shown. Due to an adjustment of prior periods comparative figures for the balance sheet, the core RoE changed by +0.1%-p compared to the published figure as of 31 December 2023. |
|||||||||||
4_ |
Excluding non-controlling interests. In 1Q 2024 Allianz reclassified certain minority interests between equity and liabilities. Prior periods comparative figures for the balance sheet have been adjusted with a minor impact on shareholders’ equity only (reduced by EUR 0.2bn as of 31 December 2023). |
|||||||||||
5_ |
Risk capital figures are group diversified at 99.5% confidence level. Solvency II capitalization ratio reflects a quarterly dividend accrual and does not include the application of transitional measures for technical provisions (the impact of which, as of 1Q 2024, amounted to +20%-p). |
RELATED LINKS |
Media Conference
May 15, 2024, 11 AM CEST: YouTube English line
Analyst Conference
May 15, 2024, 2:30 PM CEST: YouTube English line
Results
The results and related documents can be found in the download center.
UPCOMING EVENTS |
Financial Results 2Q 2024
August 8, 2024
More information can be found in the financial calendar.
About Allianz
The Allianz Group is one of the world's leading insurers and asset managers with around 125 million* private and corporate customers in nearly 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 746 billion euros** on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 1.8 trillion euros** of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2023, over 157,000 employees achieved total business volume of 161.7 billion euros and an operating profit of 14.7 billion euros for the group.
* Including non-consolidated entities with Allianz customers. |
** As of March 31, 2024. |
These assessments are, as always, subject to the disclaimer provided below.
Cautionary note regarding forward-looking statements
This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.
Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including and related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.
No duty to update
Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.
Other
The figures regarding the net assets, financial position and results of operations have been prepared in conformity with International Financial Reporting Standards. This Quarterly Earnings Release is not an Interim Financial Report within the meaning of International Accounting Standard (IAS) 34. This is a translation of the German Quarterly Earnings Release of the Allianz Group. In case of any divergences, the German original is binding.
Privacy Note
Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514050487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom